Gilead ha fatto richiesta in Europa per l’approvazione accelerata della PrEP iniettabile ogni 6 mesi https://www.gilead.com/company/company-statements/2025/gilead-submits-marketing-authorization-applications-to-european-medicines-agency-for-twice-yearly-lenacapavir-for-hiv-prevention